Drug Trial Radar · NCT04755920
SGM-101 in Colorectal Brain Metastases.
Last checked: Nov 19, 2026Latest source record: May 9, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
10
Planned (sponsor's estimate)
Start
Jan 1, 2024
Primary completion
Feb 2026
Study completion Feb 2026
Sponsor
- Lead sponsor
- Leiden University Medical CenterAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Medical Center Haaglanden; Surgimab
- First posted
- Feb 16, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study assesses the feasibility of SGM-101, a fluorochrome-labeled anti-carcinoembryonic antigen monoclonal antibody, for intraoperative near-infrared fluorescence imaging of colorectal brain metastases by injecting SGM-101 intravenously 3 - 5 days prior to surgery.
Conditions
- Rectal Neoplasms
- Rectum Cancer
- Colorectal Neoplasms
- Brain Metastases
- Brain Neoplasms
- Brain Diseases
- Brain Cancer
- Brain Tumor
- Intestinal Neoplasms
- Gastrointestinal Neoplasms
- Gastrointestinal Cancer
- Gastrointestinal Disease
- Intestinal Disease
Interventions
SGM-101Drug
Fluorescence-guided surgery
Primary outcomes
What the sponsor says the trial is designed to measure.
- To determine the feasibility of SGM-101 for intraoperative imaging of colorectal brain metastases.Time frame: Intraoperative
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Leiden University Medical Center
Leiden, Netherlands · Recruiting
Medical Center Haaglanden
The Hague, Netherlands · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.